Esketamine - Impax Laboratories

Drug Profile

Esketamine - Impax Laboratories

Alternative Names: IPX 237; IPX237-C0001; IPX237-C0002; IPX237-L0001

Latest Information Update: 14 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator IMPAX Laboratories
  • Class Analgesics; Antidepressants; Chlorobenzenes; Cyclohexanones; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Unspecified

Most Recent Events

  • 01 Jan 2015 Impax Laboratories completes a phase I trial in Healthy volunteers in Australia (ACTRN12614000444684)
  • 03 Jun 2014 Impax Laboratories completes a phase I trial in Undefined indication in Australia (ACTRN12613001097730)
  • 01 Oct 2013 Preclinical trials in Undefined indication in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top